TherapeuticsMD, Inc. (TXMD)

TherapeuticsMD, Inc. (TXMD) stock has experienced significant appreciation over the past six months, with a 100.97% increase from April 14, 2025, to April 10, 2026, and a 109.13% rise over the last 12 months. Key events include the announcement of full year 2025 financial results on March 30, 2026, where the company reported increased license revenue and improved net loss, leading to a 1.5% gain in TXMD shares. The company also announced its third-quarter 2025 financial results on November 12, 2025. In December 2022, TherapeuticsMD transitioned to a pharmaceutical royalty company, streamlining its focus to collecting license revenues.

There is no specific information available regarding the demand seasonality for TherapeuticsMD, Inc.'s products and services. The company's current model as a pharmaceutical royalty company means direct product demand seasonality would primarily impact its licensees, and subsequently, its royalty revenues.

TherapeuticsMD, Inc. operates as a pharmaceutical royalty company based in Boca Raton, Florida, focusing on the healthcare sector, specifically the Drug Manufacturers - Specialty & Generic industry. The company has transitioned to collecting royalties from licensees instead of direct research, development, or commercial operations. Its major products, commercialized through a license agreement with Mayne Pharma, include IMVEXXY for dyspareunia, BIJUVA for vasomotor symptoms, ANNOVERA as a contraceptive vaginal system, and prescription prenatal vitamin products under the BocaGreenMD and vitaMedMD brand names.

TherapeuticsMD, Inc. primarily operates in the United States, selling its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors within this region.

Specific information detailing TherapeuticsMD, Inc.'s brand reputation in the past year or events affecting it is not readily available. The company's shift to a pharmaceutical royalty model in December 2022 has likely diminished its public-facing brand activities, with its reputation now more closely tied to its financial performance and the success of its licensed products through partners like Mayne Pharma.

TherapeuticsMD, Inc. (TXMD) has a mixed ownership structure comprising institutional, insider, and retail investors. Institutional investors hold approximately 29.25% to 30.74% of the stock, with major holders including Rubric Capital Management LP and Vanguard Group Inc. Insiders own between 1.56% and 6.45% of the company's stock, with notable individual shareholders including Brian Bernick and Robert G. Finizio. Retail investors, along with public companies and individual investors, hold a significant portion, around 70.71%.